返回成功案例
医疗健康

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.

PanTera, an IBA and SCK CEN joint venture, aims to secure the large-scale production of actinium-225 (225Ac), which is one of the most promising alpha-emitting radioisotopes to fight cancer. The funds raised will be used primarily toward the construction of a state-of-the-art production facility in Belgium. This facility will not only enable large-scale production, it will also help fulfill PanTera’s ultimate goal to improve the accessibility of future, innovative cancer therapy based on 225Ac and theranostics.

Oaklins’ team in Belgium acted as the sole financial advisor in this transaction.

联系交易团队

Cédric Michils

董事总经理
布鲁塞尔, 比利时
Oaklins KBC Securities

Bart Delusinne

董事总经理
布鲁塞尔, 比利时
Oaklins KBC Securities

Nicolas Lambers

副总监
布鲁塞尔, 比利时
Oaklins KBC Securities

Michaël Rixhon

副总监
布鲁塞尔, 比利时
Oaklins KBC Securities

Nicholas Matthyssens

高级经理
布鲁塞尔, 比利时
Oaklins KBC Securities

Robin Bundervoet

经理
布鲁塞尔, 比利时
Oaklins KBC Securities

Niels Maes

经理
布鲁塞尔, 比利时
Oaklins KBC Securities

相关交易

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
医疗健康

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

更多信息
Afric Phar has been acquired by Pharma Capital
医疗健康

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

更多信息
Xiel Limited has been acquired by MIS Healthcare
私募基金 | 医疗健康

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

更多信息